Skip to main content

Table 1 Baseline characteristics of the patients

From: Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice

Variable

n = 25

Sex, male

21 (84)

Age, years

73.2 ± 5.9

Heart failure aetiology

 Ischaemic heart disease

14 (56)

 Dilated cardiomyopathy

4 (16)

 Other/Not known

7 (28)

LVEF, %

36.4 ± 8.9

Hypertension, yes

25 (100)

 Systolic BP, mmHg

129.1 ± 20.3

 Diastolic BP, mmHg

70.3 ± 14.9

Antihypertensive drugs, number

2 (1.5–3)

 RAS blocker, yes

15 (60)

 Beta-blocker, yesa

23 (95.8)

 MRA, yes

11 (44)

 Furosemide, yesb

17 (73.9)

Diabetes, yes

17 (68)

Dyslipidaemia, yes

23 (92)

Serum creatinine, mg/dL

2.2 ± 0.6

eGFR, mL/min/1.73m2

29.4 ± 8.3

Potassium, mEq/L

4.61 ± 0.6

PCR, mg/g

56.4 (26.3–427)

Visits to EDc, number

1 (0–2)

  1. Values are given as n (%), mean ± SD, and median (IQR)
  2. Abbreviations: BP Blood pressure, ED Emergency Department, eGFR Estimated glomerular filtration rate, calculated by CKD-EPI equation, LVEF Left ventricular ejection fraction, MRA Mineralocorticoid receptor antagonist, PCR urine protein/creatinine ratio; RAS: renin–angiotensin–aldosterone system
  3. Only available in 24 patients
  4. Only available in 23 patients
  5. Due to congestive symptoms. Value represents those visits over one year prior to administration of sacubitril/valsartan